Business Of Biotech

Ben Comer
  • 5.0（1）
  • マネージメント
  • アップデート：毎週

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

  1. 20時間前

    Getting To A First Product Approval With Celcuity's Brian Sullivan

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of FDA's Real-Time Oncology Review, and managing downside risk while advancing new indications, all while building a launch-ready company without losing pipeline momentum.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  2. 8月10日

    Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health centers to establish new trial sites), and why biotech leaders have a responsibility to speak up about federal policies shaping the life sciences innovation ecosystem.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  3. 8月3日

    A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients. Annette and Andrew share the story of Gomekli, a formerly shelved Pfizer drug candidate spun out into SpringWorks Therapeutics, and approved in 2025 for NF Type 1 tumors (Merck KGaA subsequently acquired SpringWorks for $3.9 billion). They also detail plans for bringing more shelved candidates back into development, using a shared data infrastructure and a matchmaking tool to pair interested drug developers with investors and funding.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  4. 7月27日

    Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Aris Baras, M.D., SVP, Head of Regeneron Genetics Center (RGC) and Co-Head of Regeneron Genetic Medicines, talks about using large-scale human genetics to find better drug targets based on "superhuman" variants. Aris explains how multi-omics, linked health records, and AI are helping developers move faster in the clinic and reduce the odds of failure, while also pushing biotech toward earlier disease prediction and more preventive care.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  5. 7月20日

    Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the Phase 3 trial. He also talks about building value through HEOR and payer engagement in parallel with clinical development, and pricing in the context of policy changes and shifting global launch dynamics.            Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  6. 7月13日

    BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

    We love to hear from our listeners. Send us a message. On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk. We dig into what biotech leaders owe patients and the public, how innovation and capital can migrate out of the U.S., and what it takes to build biotech companies that last. Dr. Levin talks about his recently published book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, what he learned during the writing process, and offers advice for first-time biotech CEOs.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  7. 7月6日

    BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.

    We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  8. 6月29日

    Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.

    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.   Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

すべて見る（320）

番組について

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

情報

  • クリエイター
    Ben Comer
  • 配信期間
    20年 - 26年
  • エピソード
    320
  • 制限指定
    不適切な内容を含む
  • Copyright
    © 2026 Business Of Biotech
  • 番組のWebサイト
    Business Of Biotech

その他のおすすめ